"Rosacea is a common inflammatory skin disorder mediated by the dysregulation of both keratinocytes and T cells. Here, we report that aquaporin 3 (AQP3), a channel protein that mediates the transport of water/glycerol, was highly expressed in the epidermis and CD4+ T cells of both rosacea patients and experimental mice....Our findings reveal that AQP3-mediated activation of NF-κB in keratinocytes and activation of STAT3 in CD4+ T cells acted synergistically and contributed to the inflammation in rosacea." [1] "Aquaporin 3 (AQP-3) is the protein product of the human AQP3 gene." [2] "Aquaporins (AQPs) are water channels that facilitate transepithelial water transport across plasma membranes following an osmotic gradient [3]. AQPs are glycosylated integral membrane proteins and widely expressed in bacteria (for review [4]), yeast [5], plants [6] (for review [7]), and mammals..." [3] Obviously we need more rosacea research on this subject. Do you want to support such targeted research? Join the RRDi and post in this thread. A Graphical abstract of AQP3 [4] End Notes [1] PubMed RSS Feed - -Targeting Aquaporin-3 Attenuates Skin Inflammation in Rosacea  [2] Aquaporin-3, Wikipedia [3] Aquaporin-3 in Cancer Saw Marlar, Helene H. Jensen, Frédéric H. Login, and Lene N. Nejsum Int J Mol Sci. 2017 Oct; 18(10): 2106. Published online 2017 Oct 7. doi: 10.3390/ijms18102106 [4] Biochimica et Biophysica Acta (BBA) - Biomembranes Volume 1861, Issue 4, 1 April 2019, Pages 768-775 Single-channel permeability and glycerol affinity of human aquaglyceroporin AQP3 Roberto A. Rodriguez, Huiyun Liang, Liao Y. Chen, Germán Plascencia-Villa, George Perry 

"In fact, rosacea might be underreported and underdiagnosed in populations with skin of color because of the difficulty of discerning erythema and telangiectasia in dark skin. The susceptibility of persons with highly pigmented skin to dermatologic conditions like rosacea, whose triggers include sun exposure, is probably underestimated. Many people with skin of color who have rosacea might experience delayed diagnosis, leading to inappropriate or inadequate treatment; greater morbidity; and uncontrolled, progressive disease with disfiguring manifestations, including phymatous rosacea." Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience Andrew F. Alexis MD, MPH, Valerie D. Callender MD, Hilary E. Baldwin MD, Seemal R. Desai MD, Marta I. Rendon MD, Susan C. Taylor MD  Journal of the American Academy of Dermatology Volume 80, Issue 6, June 2019, Pages 1722-1729.e7